
T3D Therapeutics Inc Profile last edited on: 12/17/2019
CAGE: 716M0
UEI: NNGUW8XDL245
Business Identifier: Remedial therapeutics for Alzheimers disease and other CNS disorders Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
68 TW Alexander Drive PO Box 13628
Research Triangle Park, NC 27709
Research Triangle Park, NC 27709
(919) 237-4897 |
info@t3dtherapeutics.com |
www.t3dtherapeutics.com |
Location: Single
Congr. District: 04
County: Durham
Congr. District: 04
County: Durham
Public Profile
In 2019, T3D Therapeutics was awarded the first increment of what could be a $9M grant from National Institutes for Aging to fund Phase II clinical trial for the firm's leading candidate, T3D-959, an orally administered daily treatment for Alzheimers. T3D has an exclusive, worldwide license for T3D-959 and structurally-related molecules -- an optimal therapeutic for the treatment of Alzheimers Disease (AD). TT3D-959 has advanced successfully through Phase 1 human clinical trials showing evidence of pharmacological activity and no reported safety concerns. This drug has the potential to be a transformational therapy by acting in a multi-faceted manner to improve most of the defects (pathologies) of AD, including a likely trigger for the disease, insulin and IGF-resistance. This potential disease-modifying therapeutic is an orally-delivered, once a day medicine for AD patients with mild to moderate disease severity and potentially patients with mild cognitive impairment (MCI). Additionally, the mechanism of action of T3D-959 may provide therapeutic benefit in other central nervous system (CNS) disorders. The Companys vision is to develop the product through a series of three stage gates culminating in a Phase 2b clinical trial. Each stage gate provides a potential opportunity for an investor exit through sale or out-licensing of T3D-959 to a large pharmaceutical company. Development is executed in a capital-efficient, virtual operation that minimizes infrastructure and personnel costs.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 1 | NIH | $1,249,334 | |
Project Title: Clinical Development Enablement - Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimer's Disease Drug Candidate T3D-959 | ||||
2023 | 2 | NIH | $1,618,550 | |
Project Title: Phase 2 Enabling Studies of a Candidate Drug Therapy (T3D-959) Regulating Neurometabolism for the Treatment of Huntington's Disease | ||||
2016 | 2 | NIH | $1,914,894 | |
Project Title: Clinical Evaluation of T3D-959 as a Potential Disease Remedial Therapeutic for the Treatment of Alzheimer's Disease |
Key People / Management
John Didsbury -- President, CEO and Founder
Stanley D Chamberlain -- Chief Scientific Officer
Hoda Gabriel -- Sr. Director, Clinical Development
Warren Strittmatter -- Chief Medical Officer
Ching-Hong Yang
Stanley D Chamberlain -- Chief Scientific Officer
Hoda Gabriel -- Sr. Director, Clinical Development
Warren Strittmatter -- Chief Medical Officer
Ching-Hong Yang